1. "2019"
Formats
  1. Journal Article (2145)
  2. Meeting Abstract (2088)
  3. Review (529)
  4. Editorial (275)
  5. Book Section (252)
  6. Guidelines (108)
  7. Correspondence (89)
  8. Research Letter (47)
  9. Conference Paper (44)
  10. Miscellaneous (25)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)

More Groups

People
  1. Sergio Giralt (97)
  2. Marc Ladanyi (96)
  3. Maria Arcila (84)
  4. Miguel-Angel Perales (82)
  5. Alexander Drilon (76)
  6. David Hyman (74)

More People

Years
  1. 2019 (5612)
Publications
  1. Journal of Clinical Oncology (457)
  2. Blood (268)
  3. Cancer Research (192)
  4. Annals of Oncology (163)
  5. International Journal of Radiation Oncology, Biology, Physics (124)
  6. Modern Pathology (112)

More Publications

Publishers
  1. Elsevier Inc. (696)
  2. American Society of Clinical Oncology (518)
  3. Springer (445)
  4. American Association for Cancer Research (343)
  5. Nature Publishing Group (337)
  6. Oxford University Press (325)

More Publishers

Results (5612)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057
    Meeting Abstract

    De Wit, R.; Kulkarni, G. S.; Uchio, E. M.; Krieger, L. E. M.; Boormans, J. L.; Roumiguié, M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A framework for building a clinically relevant risk model
    Meeting Abstract

    Daly, R. M.; Gorenshteyn, D.; Gazit, L.; Sokolowski, S.; Nicholas, K.; Perry, C.; Adams, L.; Baldwin, A.; Holland, J. C.; Zervoudakis, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial
    Meeting Abstract

    Colombo, N.; Moore, K. N.; Scambia, G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A. S.; Floquet, A.; Leary, A.; Sonke, G. S.; Gourley, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Validation of a panel of risk factors for predicting breast cancer reappearance
    Meeting Abstract

    Corso, G.; Veronesi, P.; Maisonneuve, P.; Goldhirsch, A.; Sacchini, V.; Caldarella, P.; De Scalzi, A. M.; Galimberti, V.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC)
    Meeting Abstract

    Comen, E. A.; Bryce, Y.; Page, D. B.; Solomon, S. B.; Rodine, M.; Abaya, C. D.; Morris, E. A.; Plitas, G.; El-Tamer, M.; Gemignani, M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Pilot study of NKTR214 and nivolumab in patients with sarcomas
    Meeting Abstract

    D'Angelo, S. P.; Conley, A. P.; Kelly, C. M.; Dickson, M. A.; Gounder, M. M.; Chi, P.; Keohan, M. L.; Livingston, J. A.; Patel, S.; Adamson, T.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Cell cycle progression score differentiates indolent from aggressive prostate cancer in men diagnosed by TURP
    Meeting Abstract

    Cuzick, J. M.; Stone, S.; Rajamani, S.; Moller, H.; Berney, D. M.; Cohen, T.; Scardino, P. T.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3
    Meeting Abstract

    Coleman, R. L.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A. P.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase Ia/Ib, open label, multicenter, dose -escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors
    Meeting Abstract

    Chong, C. R.; Bauer, T. M.; Laurie, S. A.; Patel, M. R.; Yamamoto, N.; Davenport, T.; Geng, J.; Gibson, N.; Vallaster, M. P.; LoRusso, P.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study)
    Meeting Abstract

    Cho, B. C.; Drilon, A. E.; Doebele, R. C.; Kim, D. W.; Lin, J. J.; Lee, J.; Ahn, M. J.; Zhu, V. W.; Ejadi, S.; Camidge, D. R.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save